Akari Therapeutics Plc IPO year
What is the IPO year of Akari Therapeutics Plc?
The IPO year of Akari Therapeutics Plc is 2013
What is the definition of IPO year?
Initial public offering is a type of public offering in which shares of a company usually are sold to institutional investors that in turn, sell to the general public, on a securities exchange, for the first time.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO year of companies in the Health Care sector on NASDAQ compared to Akari Therapeutics Plc
What does Akari Therapeutics Plc do?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Companies with ipo year similar to Akari Therapeutics Plc
- AMG Capital Trust II has IPO year of 2012
- Live Nation Entertainment has IPO year of 2012
- MGM Resorts International has IPO year of 2012
- EnerSpar has IPO year of 2012
- The Western Union has IPO year of 2012
- Wameja has IPO year of 2012
- Akari Therapeutics Plc has IPO year of 2013
- Opus Bank has IPO year of 2014
- Recro Pharma Inc has IPO year of 2014
- Radius Recycling has IPO year of 2014
- Progenity has IPO year of 2014
- Axalta Coating Systems Ltd has IPO year of 2014
- Anevia SA has IPO year of 2014